A federal judge has nixed the proposed $100 million settlement by one of the defendants named in the massive fen-phen and Redux diet-drug litigation, finding that the class action fell short of the strict rules that govern such “limited fund” settlements.

The ruling by Senior U.S. District Judge Louis C. Bechtle means that Interneuron Pharmaceuticals Inc. must continue to defend itself against a slew of lawsuits in both the state and federal courts.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]